Cornell has funded studies for cats with injection site sarcomas

(#1) Study title: DNA damage response mechanisms and chemosensitivity of feline injection site sarcomas

Inclusion criteria: Cats with measurable tumors (greater than 2 cm) suspected of having injection site sarcoma based on location and cytological evaluation (tumors may be primary, recurrent, or metastatic.)

Purpose: Determine whether alterations in DNA damage response mechanisms impact whether or not a given tumor is susceptible to chemotherapy. This study involves collection of tumor biopsies and in vitro laboratory analysis of those biopsies.

Benefit: Client receives $370 towards final bill.

(#2) Study title: Individualized dosing of carboplatin in cats with injection site sarcomas

Inclusion criteria: Cats with histological confirmation of tumor type and a measurable primary tumor or metastatic lesion.

Purpose: Determine the response rate and toxicity of carboplatin treatment (dosage based on GFR) in cats with injection site sarcomas. It is hypothesized that individualized dosing of carboplatin based on kidney function will be effective and well tolerated.

Benefit: Study pays for cost of GFR, two carboplatin treatments, and CBC monitoring after treatment.

For additional information, please contact Dr. Kelly Hume or Dr. Cheryl Balkman of the Cornell University Hospital for Animals Oncology Service at 607-253-3060 or email vet-research@cornell.edu.